These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8112136)

  • 1. [The future application of adoptive immunotherapy in treatment of lung cancer].
    Li PS
    Zhonghua Nei Ke Za Zhi; 1993 Sep; 32(9):579-80. PubMed ID: 8112136
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical application of adoptive immunotherapy in patients with progressive lung cancer].
    Cho T; Yoshizawa H
    Nihon Naika Gakkai Zasshi; 1994 Sep; 83(9):1543-8. PubMed ID: 7798747
    [No Abstract]   [Full Text] [Related]  

  • 3. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT; Kradin RL
    Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment with autologous tumor-infiltrating lymphocytes and recombinant interleukin-2 in patients with lung carcinoma].
    Li D; Zhang X; Song Y
    Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):152-5. PubMed ID: 7656811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.
    Munari L; Silvani A; Passerini CG; Radrizzani M; Parmiani G; Boiardi A
    J Neurosurg Sci; 1990; 34(3-4):283-8. PubMed ID: 1965907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intrapleural administration of LAK cells combined with rIL2 in the treatment of advanced lung cancer with malignant pleural effusion].
    Mao G; Gao Z; Wang Q
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):83-4, 127. PubMed ID: 7553956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
    Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
    Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A regimen of surgical adjuvant immunotherapy for cancer with interleukin 2 and lymphokine-activated killer cells. Basis, clinical toxicity, and immunomodulatory effects.
    Yano T; Ishida T; Yoshino I; Murata M; Yasumoto K; Kimura G; Nomoto K; Sugimachi K
    Biotherapy; 1991; 3(3):245-51. PubMed ID: 1854593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model.
    Rodolfo M; Salvi C; Bassi C; Sensi M; Parmiani G
    Ann Ist Super Sanita; 1990; 26(3-4):423-32. PubMed ID: 2091504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of interleukin-2 in treating cancer.
    Patterson DL; Wiemann MC
    Indiana Med; 1991 Aug; 84(8):534-7. PubMed ID: 1918915
    [No Abstract]   [Full Text] [Related]  

  • 11. [Adjuvant immunotherapy for lung cancer].
    Kawamura M
    Nihon Rinsho; 2002 May; 60 Suppl 5():459-62. PubMed ID: 12101714
    [No Abstract]   [Full Text] [Related]  

  • 12. Interleukin 2 in cancer therapy.
    Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
    Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A history and prospect of adoptive immunotherapy against malignant glioma--past, now and future].
    Nitta T
    No To Shinkei; 1992 Jul; 44(7):605-13. PubMed ID: 1419336
    [No Abstract]   [Full Text] [Related]  

  • 14. [Lymphokine-activated killer cell adoptive immunotherapy for cancer treatment and its significance].
    Toge T; Yamaguchi Y
    Hum Cell; 1992 Sep; 5(3):218-25. PubMed ID: 1334695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA; Benyunes MC; Bianco JA; Fefer A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract]   [Full Text] [Related]  

  • 16. [Dynamics of cytotoxicity of blood mononuclear cells in patients with bladder cancer during endolymphatic immunotherapy with lymphokine- activated killer cells and recombinant interleukin-2].
    Malakhova NV; Figurin KM; Fedorova NS; Kiselevskiĭ MV; Bykovskaia SN
    Biull Eksp Biol Med; 1996 Feb; 121(2):188-91. PubMed ID: 9026128
    [No Abstract]   [Full Text] [Related]  

  • 17. [Observation of the effects of LAK/IL-2 therapy combining with Lycium barbarum polysaccharides in the treatment of 75 cancer patients].
    Cao GW; Yang WG; Du P
    Zhonghua Zhong Liu Za Zhi; 1994 Nov; 16(6):428-31. PubMed ID: 7720497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Augmentation of therapeutic effect of adoptive immunotherapy through a synergy between transferred killer cells and host's fresh lymphocytes].
    Kan N; Yamasaki S; Harada T; Satoh K; Ichinose Y; Moriguchi Y; Kodama H; Ohgaki K
    Hum Cell; 1992 Sep; 5(3):236-42. PubMed ID: 1467322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokines in anticancer therapy.
    Khan IU; Shear NH
    Clin Dermatol; 1991; 9(4):523-33. PubMed ID: 1726586
    [No Abstract]   [Full Text] [Related]  

  • 20. Adoptive cellular therapy.
    Urba WJ; Longo DL
    Cancer Chemother Biol Response Modif; 1990; 11():265-80. PubMed ID: 2223395
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.